DexCom, Inc. (DXCM) AI Stock Analysis

DexCom, Inc. is a medical device company that specializes in continuous glucose monitoring (CGM) systems for diabetes management. Its systems provide real-time glucose data to individuals and healthcare providers. The flagship DexCom G6 integrated CGM reduces the need for routine finger sticks, while the newer Dexcom G7 advances user experience and technological capabilities. The company also offers the Dexcom Real-Time API for digital health integration and Dexcom Share for remote monitoring. DexCom collaborates with Verily Life Sciences LLC and Verily Ireland Limited, marketing directly to endocrinologists, physicians, and diabetes educators.

Revenue increased from $2.45B in FY2021 to $4.66B in FY2025, delivering a 5-year CAGR of 19.3% from FY2020 to FY2025. Over this period, annual net income grew from $216.9M in FY2021 to $836.3M in FY2025, while diluted EPS expanded from $0.66 to $2.09. Gross margin contracted from 68.6% in FY2021 to 60.1% in FY2025, but operating margin rose from 10.9% to 19.6%. For the trailing twelve months ending June 30, 2026, revenue stood at $4.97B with a 24.3% operating margin. In the latest quarter ended June 30, 2026, revenue grew 13.1% year-over-year, and earnings grew 43.6%.

As of June 30, 2026, DexCom held $1.95B in cash and short-term investments against $1.40B in total debt, resulting in net cash of $548.6M. The company reported a current ratio of 1.73 and a debt-to-equity ratio of 0.53, with total assets of $6.46B and shareholders' equity of $2.62B. In FY2025, DexCom generated $1.44B in operating cash flow and $1.08B in free cash flow. Capital expenditures totaled $363.5M and share buybacks reached $500.0M in FY2025.

DexCom trades at a trailing P/E of 34.1x and a forward P/E of 28.2x, compared with the median of its Nasdaq-100 Healthcare peers of 28.9x and 19.7x, respectively. Its price-to-sales multiple is 6.5x, matching the median of its Nasdaq-100 Healthcare peers of 6.5x, while its EV/EBITDA of 20.9x sits below the peer median of 24.5x. Over the past year, DexCom stock gained 29.7%, outpacing the S&P 500 return of 16.8%. Over five years, the stock fell 36.8%, compared with an 83.0% gain for the S&P 500.

Of the 29 analysts covering DexCom, 22 rate it a Strong Buy, 4 rate it a Buy, and 3 rate it a Hold, with 0 Sell or Strong Sell ratings. The mean price target of $96.46 represents an upside of 12.1% from the last close of $86.04. For the fiscal year ending December 31, 2026, analysts estimate EPS of $2.66 and revenue of $5.23B. DexCom has beaten EPS estimates in 4 of the last 4 quarters, and its next earnings date is October 29, 2026.

This page is an AI-written research summary of DexCom, Inc. (DXCM). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: DXCM income statement, DXCM balance sheet, DXCM key metrics, DXCM analyst forecast, DXCM chart. See the DXCM stock overview for the latest quote and news.